Document is current
Any future updates will be listed below
-
Authors
Bibeau, Kristen https://orcid.org/0000-0002-6871-2333
Butler, Kathleen https://orcid.org/0000-0002-6907-0846
Wang, Mingyue
Skaltsa, Konstantina
Hamzavi, Iltefat H. https://orcid.org/0000-0002-3137-5601
-
Funding
Funding for this research was provided by:
Incyte
- License Information
-
More Information
Article History
Received: 14 May 2024
Accepted: 25 June 2024
First Online: 30 July 2024
Declarations
:
: Kristen Bibeau (currently Moderna), Kathleen Butler (currently Astria Therapeutics, Inc.), and Mingyue Wang (currently Boehringer Ingelheim) are former employees of Incyte Corporation and are shareholders of Incyte. Konstantina Skaltsa is an employee of IQVIA contracted by Incyte Corporation to perform the psychometric analysis reported in this article. Iltefat H Hamzavi has served as an advisory board member for AbbVie; as a consultant for Boehringer Ingelheim, Galderma Laboratories LP, Incyte Corporation, Pfizer, and UCB; as a principal investigator for Avita, Bayer, Estée Lauder, Ferndale Laboratories, Incyte Corporation, Lenicura, L’Oréal, Pfizer, and Unigen; as a subinvestigator for Arcutis; as president of the HS Foundation; and as board member of the Global Vitiligo Foundation.
: The trial protocols were approved by an institutional review board or ethics committee at participating centers. Trials were conducted in accordance with the Declaration of Helsinki and adhered to trial protocols, Good Clinical Practice, and applicable country-specific laws and regulations. Written informed consent or assent was provided by all patients.
